2,914 material Form 8-K filings that 2,352 companies we cover made with the SEC in August 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Precipio reported second-quarter 2026 revenue of $7.0 million, up from $6.7 million in the first quarter and 22% above the $5.7 million in the year-earlier quarter. Adjusted EBITDA, a non-GAAP measure, was $0.4 million, compared with a $(0.2) million loss in the first quarter, but the company's GAAP net result was a loss of $(0.2) million versus net income of $0.1 million a year earlier.
Q2 2026 revenue was $7.0 million, including $6.1 million in pathology revenue and $0.9 million in product revenue.
Adjusted EBITDA was $0.4 million in Q2 2026, versus $(0.2) million in Q1 2026.
GAAP net loss was $(0.2) million in Q2 2026, compared with net income of $0.1 million in Q2 2025.
Cash was over $3 million at quarter end, versus $1.1 million in Q2 2025, with $0.7 million generated from operations in the quarter.
MediaCo reported second-quarter 2026 net revenues of $34.0 million, up 9% from a year earlier, driven by digital advertising. Net loss widened 17% to $8.6 million, and Adjusted EBITDA fell 38% to $0.9 million, so higher revenue did not translate into better profitability for shareholders.
Q2 2026 net revenues were $34.0 million ($33,969 thousand), up 9% from $31.2 million in Q2 2025.
Q2 2026 net loss was $8.6 million, compared with $7.4 million a year earlier, citing higher operating and corporate expenses and interest costs.
Q2 2026 Adjusted EBITDA was $0.9 million, down from $1.5 million in Q2 2025.
First-half 2026 net revenues were $65.4 million, up 10%, while the first-half net loss was $18.0 million versus $16.0 million.
Retractable Technologies reported second-quarter 2026 net sales of $7.2 million, down from $10.4 million a year earlier, with an operating loss of $5.1 million in both periods. The company attributed the sales decline mainly to the timing of EasyPoint needle orders and to unusually high flu season unit sales in the second quarter of 2025. Second-quarter net income of $2.8 million was driven by a $6.4 million gain on the sale of equity securities, while the first half shows a net loss of $1.4 million and a wider operating loss of $11.3 million.
Q2 2026 net sales were $7.2 million versus $10.4 million in Q2 2025; operating loss was $5.1 million in both periods.
First-half 2026 net sales were $14.4 million versus $18.7 million; operating loss widened to $11.3 million from $9.8 million.
Q2 2026 net income of $2.8 million included a $6.4 million realized gain on sale of equity; first-half net loss was $1.4 million.
A reduction in force in April 2026 is expected to produce cost savings in future periods.
Canton Strategic Holdings reported its first operating revenue for the quarter ended June 30, 2026, $1,495,859, compared with $0 a year earlier. The company also posted a net loss of $19,254,826, or $(0.08) per share, which includes a $23,735,950 unrealized loss on its Canton Coin holdings, so the larger loss and the revenue gain both bear on shareholder returns.
Total revenue was $1,495,859 for the three months ended June 30, 2026, versus $0 in the same period of 2025; the filing says the LaaS offering drove about $1.3 million of it.
Net loss was $19,254,826, or $(0.08) per basic and diluted share from continuing operations, including a $23,735,950 unrealized loss on digital asset holdings.
Cash and cash equivalents were $37,241,568 as of June 30, 2026, up from $12,007,148 as of December 31, 2025.
The sale of Gravitas Life Sciences, Inc. closed on July 17, 2026, for an unsecured promissory note of $3,500,000 bearing 15% payment-in-kind interest, plus contingent milestone payments.
Air T reported fiscal 2027 first-quarter results for the period ended June 30, 2026, with revenue up 63% to $115.5 million but an operating loss of $12.8 million compared with operating income of $0.8 million a year earlier. The company attributed the loss mainly to transaction and integration costs for Crestone's June 10 acquisition of Arena Aviation Capital and to depreciation from the fair-value step-up of the Rex aircraft fleet. Shareholders are seeing higher revenue alongside lower profitability in the quarter.
Q1 revenue was $115.5 million, up $44.6 million, or 63%, from the prior-year quarter.
Q1 operating loss was $12.8 million versus operating income of $0.8 million a year earlier; Adjusted EBITDA was $0.8 million, down 45% from $1.5 million.
Trailing twelve-month revenue was $371.7 million, up 25%, while the trailing twelve-month operating loss was $24.9 million.
Crestone acquired Arena Aviation Capital on June 10 for $33.9 million, including $21.7 million in cash and $12.2 million of contingent consideration; Blue Owl funded $10.0 million for preferred units representing 10.25% of the platform.
Nakamoto reported second-quarter 2026 results on August 13, 2026, with total operating revenue of $35.9 million, an operating loss of $149.1 million, and a net loss of $133.0 million, or $6.65 per diluted share. The company said the losses were driven mainly by $105.2 million of non-cash goodwill impairment charges and $48.7 million of mark-to-market losses on digital assets. Shareholders face a large GAAP loss even though the company reported $7.3 million of adjusted operating income and reduced debt by about $45 million.
Total operating revenue was $35.9 million for the quarter ended June 30, 2026; the prior-year quarter shows no revenue figures in the filing.
Net loss was $133.0 million, or $6.65 per diluted share, compared with a net loss of $2.4 million in the second quarter of 2025.
Adjusted operating income, a non-GAAP measure, was $7.3 million, which the company said was its first positive adjusted operating income since becoming a Bitcoin operating company.
As of June 30, 2026, the company held 4,467 Bitcoin with an aggregate fair value of approximately $261.5 million and authorized a share repurchase program of up to $25 million.
Air T reported fiscal first-quarter 2027 revenue of $115.5 million, up 63% from a year earlier, with $55.9 million coming from its Rex regional airline acquisition completed on December 18, 2025. The company swung to an operating loss of $12.8 million from operating income of $0.8 million a year earlier, and net loss per share was $5.86 versus $0.61, so higher sales did not translate into profit for shareholders.
Revenue $115.5 million, up $44.6 million or 63%; Rex contributed $55.9 million
Operating loss $12.8 million versus operating income of $0.8 million in the prior-year quarter
Net loss per share $5.86 versus $0.61; loss before income taxes $15.0 million versus $0.8 million
Adjusted EBITDA (a non-GAAP measure) $0.8 million versus $1.5 million; Regional Airline segment cited fuel expense of $11.8 million as the primary driver of its operating loss
Maui Land & Pineapple reported results for the six months ended June 30, 2026, in Exhibit 99.1 to a Form 8-K. Total operating revenues fell to $7.1 million from $10.4 million a year earlier, while the net loss narrowed to $3.7 million from $9.6 million, mainly because the prior year included pension charges. Shareholders face lower revenue and a higher line of credit balance alongside the smaller loss.
Total operating revenues were $7.1 million for the six months ended June 30, 2026, versus $10.4 million a year earlier.
Net loss was $3.7 million, or $0.19 per share, versus $9.6 million, or $0.49 per share, a year earlier.
Land development and sales revenue was $0.5 million, down from $4.1 million; the company cited contracted sales, including a $10.0 million agreement with Harvest Church expected to close in 2027.
Cash and cash equivalents were $3.3 million at June 30, 2026, and the line of credit balance rose to $8.5 million from $4.0 million at December 31, 2025.
AgEagle reported second quarter 2026 revenue of $2.7 million, nearly double the first quarter but down from $4.1 million in the second quarter of 2025. Cash and cash equivalents fell to $15.9 million at June 30, 2026, from $29.5 million at December 31, 2025, so the sequential rebound comes with lower year-over-year sales and a smaller cash balance.
Revenue of $2.7 million, compared with $1.4 million in Q1 2026 and $4.1 million in Q2 2025
Gross margin of 50.6%, up from 41.7% in Q1 2026 but below 56% in Q2 2025
Cash and cash equivalents of $15.9 million at June 30, 2026, down from $29.5 million at December 31, 2025
Company expects continued revenue progression in the second half of 2026 but gave no numeric guidance; nine eBee VISION systems are expected to ship in Q3 2026
Traws Pharma reported its quarter ended June 30, 2026, with no revenue, compared with $2.7 million a year earlier, and a net loss of $3.0 million, or $0.16 per share, versus a $0.9 million loss, or $0.11 per share, in the same period of 2025. The company said its cash and equivalents, plus expected at-the-market equity proceeds, should fund operations into the first quarter of 2027, and that it may need additional financing after that.
Q2 2026 revenue was zero, down from $2.7 million in Q2 2025, which included a non-recurring deferred revenue recognition tied to a licensing termination.
Q2 2026 net loss was $3.0 million ($0.16 per share); six-month net loss was $10.2 million, compared with $20.6 million net income in the first half of 2025, which included a $26.7 million non-cash warrant gain.
Cash and cash equivalents were $5.0 million at June 30, 2026, up from $3.8 million at December 31, 2025, mainly from the April 2026 private placement and ATM sales.
Shareholders approved the Series B and Series C financing tranches on July 8, 2026; the company says access remains subject to milestones and investor participation, and the FDA clinical hold on tivoxavir marboxil is still pending resolutio
Solana Company reported a second-quarter 2026 net loss of $30.3 million, or $0.38 per share, compared with a net loss of $9.8 million in the prior-year quarter. Revenue rose to $2.5 million, mainly from staking on its SOL holdings, but operating expenses reached $35.1 million, including $6.8 million of severance tied to the divestiture of its legacy PoNS medical device business.
Q2 2026 revenue was $2.5 million, almost all staking revenue, versus $43 thousand a year earlier
Q2 2026 net loss was $30.3 million, or $0.38 per share, versus $9.8 million in the prior-year quarter
General and administrative expenses were $11.1 million, including $6.8 million of severance tied to the PoNS divestiture
Total assets were $176.1 million at June 30, 2026, down from $303.9 million at December 31, 2025, and cash was $3.6 million
Seritage Growth Properties reported second-quarter 2026 results with a net loss attributable to common shareholders of $7.4 million, or $0.13 per share, compared with $29.7 million, or $0.53 per share, a year earlier. Revenue fell sharply to $1.9 million from $4.7 million, while the company repaid its $50.0 million term loan using new loans and cash on hand, and said it continues to explore a strategic transaction.
Q2 2026 net loss attributable to common shareholders was $7.4 million ($0.13 per share), versus $29.7 million ($0.53 per share) in Q2 2025.
Q2 2026 total revenue was $1.9 million, versus $4.7 million in Q2 2025.
Six-month net loss was $38.9 million ($0.69 per share), including a $15.2 million impairment on one consolidated property.
On July 24, 2026, the company closed a $15.0 million term loan and $25.0 million revolver, drew $15.0 million, and repaid the $50.0 million term loan balance.
Cerenome reported second quarter 2026 results on August 14, 2026. Grant revenue fell to $0.4 million from $1.4 million a year earlier, the operating loss widened to $9.1 million from $1.5 million, and the company posted a net loss of $9.0 million, or $1.31 per basic share, compared with net income of $5.2 million in the prior-year quarter, which included a $6.5 million gain from a change in fair value of derivative instruments. Cash and investments totaled $8.6 million at June 30, 2026, and the company affirmed its 2026 milestones and outlook without changes.
Operating loss was $9.1 million in Q2 2026 versus $1.5 million in Q2 2025, which the company attributes mainly to expansion of CNSide commercial operations and funding of the REYOBIQ Phase 2 trial.
Net loss was $9.0 million, or $1.31 per basic share, versus net income of $5.2 million, or $0.62 per basic share, in Q2 2025.
Cash, cash equivalents and investments were $8.6 million as of June 30, 2026.
The company affirmed its 2026 milestones, including ReSPECT-GBM data expected in Q1 2027.
Smith-Midland reported second-quarter 2026 revenue of $23.4 million, down from $26.2 million a year earlier, and net income of $1.4 million, or $0.26 per diluted share, down from $4.2 million, or $0.79. The company attributed the decline mainly to a higher-margin special barrier rental project in the 2025 quarter that did not recur. Backlog was approximately $57.4 million as of August 1, 2026, up from $54 million a year earlier.
Revenue was $23.4 million versus $26.2 million; product sales were $11.2 million versus $13.4 million.
Gross margin was 23.2% versus 29.7%, mainly due to the special barrier rental project in Q2 2025 that did not recur.
Net income was $1.4 million, or $0.26 per diluted share, versus $4.2 million, or $0.79 per diluted share.
Backlog was approximately $57.4 million as of August 1, 2026, compared with $54 million one year earlier.
Enveric Biosciences reported a second-quarter 2026 net loss of $3.0 million, up from $2.5 million a year earlier, and cash on hand of $8.3 million as of June 30, 2026. The company also gave an update on its lead drug candidate EB-003, including preclinical data and the start of genotoxicity studies ahead of a planned IND submission.
Net loss attributable to stockholders was $3.0 million for the quarter ended June 30, 2026, versus $2.5 million a year earlier.
Basic and diluted loss per share was $0.76, compared with $11.65 in the second quarter of 2025.
The company raised $5.0 million in gross offering proceeds and $1.5 million from warrant exercises in the quarter.
Genotoxicity studies for EB-003 were initiated, a step the filing describes as required for IND submission.
Femasys reported that quarterly sales fell 18.9% to $331,827 in the quarter ended June 30, 2026, mainly due to lower FemVue sales, while the quarterly net loss narrowed slightly to $4.47 million from $4.59 million. The company had about $1.4 million of cash at June 30, 2026, and completed a $30 million private placement after quarter-end, which it says gives it resources for its commercial and clinical plans and restored Nasdaq listing compliance.
Quarterly sales were $331,827, down $77,441 or 18.9% from $409,268 a year earlier; six-month sales rose 0.8% to $756,716.
Quarterly net loss was $4,469,095, or $(1.33) per share, versus $4,585,922, or $(3.18) per share, a year earlier; six-month net loss was $3,622,995 versus $10,482,761.
Cash and cash equivalents were about $1.4 million at June 30, 2026, with a $30 million private placement completed after the quarter, which could bring up to $90 million if warrants are fully exercised.
The company said it regained compliance with Nasdaq Listing Requirements and appointed John Canning as Chief Operating Officer.
Motorsport Games reported second-quarter 2026 revenue of $3.5 million, up 36.6% from a year earlier, and first-half revenue of $7.6 million, up 74.0%. Net income fell to about $0.2 million from $4.2 million, and diluted EPS was $0.08 versus $0.82, because the prior-year quarter included non-recurring gains and development spending nearly tripled.
Q2 2026 revenue was $3.5 million versus $2.6 million in Q2 2025, an increase of 36.6%; six-month revenue was $7.6 million, up 74.0%.
Q2 2026 net income was about $0.2 million versus $4.2 million in Q2 2025; the prior year included $2.3 million in foreign exchange gains and a $0.8 million Wesco Settlement Agreement gain.
Non-GAAP Adjusted diluted EPS was $0.19 in Q2 2026 versus $0.25 a year earlier, and $0.33 for the six months versus $0.24; Q2 Adjusted EBITDA was $0.8 million versus $1.4 million.
Cash and cash equivalents were about $3.9 million at June 30, 2026, and $1.2 million was drawn on a $3 million Citibank revolving line of credit.
Ambow Education Holding reported unaudited results for the six months and three months ended June 30, 2026. First-half net revenues rose 2.0% to $5.2 million, but second-quarter revenue fell 14.3% and the company posted a net loss of $0.1 million, compared with net income of $1.8 million a year earlier, which included a one-time $1.5 million lease settlement gain.
Q2 2026 net revenues fell 14.3% to $2.4 million from $2.8 million, mainly due to lower HybriU licensing and sales.
Q2 2026 gross margin was 50.0%, compared with 53.6% a year earlier, and operating expenses rose 27.3% to $1.4 million.
First-half 2026 net income was $0.3 million, or $0.10 per ADS, versus $1.9 million, or $0.66 per ADS, in the first half of 2025.
Cash resources were $7.2 million as of June 30, 2026, and working capital was positive at $5.5 million.
LeonaBio reported a second-quarter 2026 net loss of $19.0 million, or $0.80 per share, up from $7.0 million, or $1.78 per share, a year earlier. The company said higher spending on the Phase 3 ELAINE-3 trial for lasofoxifene drove the increase, and cash, cash equivalents and investments fell to $51.1 million as of June 30, 2026, which shareholders may want to track against the company's funding needs.
Net loss was $19.0 million, or $0.80 per share, for the quarter ended June 30, 2026, compared with $7.0 million, or $1.78 per share, a year earlier.
R&D expenses rose to $12.9 million from $3.7 million, driven mainly by clinical trial spend for the ELAINE-3 trial.
Cash, cash equivalents and investments were $51.1 million at June 30, 2026, down from $88.3 million at December 31, 2025; net cash used in operations was $37.9 million for the quarter.
Data Storage Corp reported second-quarter 2026 sales of $358,530, up from $327,951 a year earlier, while its net loss attributable to common stockholders widened to $1,225,515 from $733,049. The company completed a tender offer that cut its share count and said it is evaluating acquisitions of recurring-revenue technology businesses, with about $9.3 million in cash and marketable securities and no long-term debt.
Q2 2026 sales rose to $358,530 from $327,951; loss from operations widened to $1,282,070 from $950,762.
Loss per share attributable to common stockholders was $(0.55) for the quarter versus $(0.10) a year earlier.
Six-month share repurchases in connection with the tender offer totaled $29,528,957; treasury stock stood at 5,625,129 shares at June 30, 2026.
Cash and cash equivalents plus marketable securities were about $9.3 million at June 30, 2026, with no long-term debt, according to management.
CSP Inc. (CSPi) reported fiscal third-quarter 2026 results for the quarter ended June 30, 2026, with sales of $14.4 million, down from $15.4 million a year earlier, and a net loss of $846,000, or $0.09 per share, compared with a net loss of $264,000, or $0.03 per share, in the prior-year quarter. Gross profit margin rose to 30.1% from 28.8%, and management said vendor hardware delivery delays are likely to continue into the first half of fiscal 2027. For shareholders, the quarter shows lower sales and a wider loss, while the board declared a quarterly dividend of $0.03 per share.
Third-quarter sales were $14.4 million, versus $15.4 million a year earlier; gross profit margin was 30.1% versus 28.8%.
Net loss was $846,000, or $0.09 per share, versus a net loss of $264,000, or $0.03 per share, a year earlier.
Nine-month net loss was $491,000, or $0.05 per share, compared with net income of $100,000, or $0.01 per diluted share, a year earlier.
Cash and cash equivalents were $24.7 million as of June 30, 2026; the board declared a $0.03 dividend payable September 15, 2026, to holders of record on August 28, 2026.
Cue Biopharma reported a second quarter 2026 revenue increase to $7.9 million from $3.0 million, but its net loss grew to $153.1 million from $8.5 million. The company attributed the larger loss mainly to one-time non-cash losses and expenses tied to its CUE-221 license agreement with Ascendant, and it had $17.4 million in cash at June 30, 2026 before a $50 million private placement completed after quarter end.
Second quarter revenue was $7.9 million, versus $3.0 million a year earlier, driven by a preclinical milestone under the Boehringer Ingelheim collaboration.
Net loss was $153.1 million, or $24.14 per share, versus $8.5 million, or $2.67 per share, in the second quarter of 2025.
Cash and cash equivalents were $17.4 million at June 30, 2026; a $50 million private placement was completed after quarter end.
Phase 2 data readout for CUE-221 in Chronic Spontaneous Urticaria is anticipated by the end of the third quarter of 2026.
Reading International reported second-quarter 2026 total revenue of $66.9 million, up 11% from $60.4 million a year earlier, and net income of $2.3 million, compared with a net loss of $2.8 million in Q2 2025. Basic earnings were $0.10 per share, against a loss of $0.12 per share a year earlier. Short-term debt rose sharply to $108.0 million as several loans come due within twelve months, and cash was $5.7 million at June 30, 2026, so shareholders will be watching how those obligations are refinanced.
Q2 2026 total revenue of $66.9 million rose 11% from $60.4 million in Q2 2025, the highest second-quarter revenue since Q2 2019.
Q2 2026 net income was $2.3 million, versus a net loss of $2.8 million in Q2 2025; basic earnings per share were $0.10 versus a loss of $0.12.
Short-term debt net of deferred finance costs was $108.0 million at June 30, 2026, up $72.0 million from December 31, 2025, mainly because Trust Preferred Securities and Emerald Creek Capital loans become due within twelve months.
Cash and cash equivalents were $5.7 million at June 30, 2026; the Bank of America facility maturity was extended to December 21, 2026, and the Santander loan to October 1, 2026.
PAVmed reported results for the quarter ended June 30, 2026, with a GAAP net loss attributable to common stockholders of $5.5 million, or $(0.87) per diluted share, compared with a loss of $13.3 million, or $(22.08) per share, a year earlier. The company also gave a business update on subsidiaries Lucid Diagnostics and Veris Health, including a first laboratory benefit manager coverage policy for EsoGuard.
GAAP net loss attributable to common stockholders was $5.5 million, or $(0.87) per diluted share, for the three months ended June 30, 2026, versus $13.3 million, or $(22.08) per share, a year earlier.
Non-GAAP adjusted loss was $1.7 million, or $(0.27) per share, for the quarter; cash and cash equivalents were $3.8 million as of June 30, 2026, up from $1.5 million at December 31, 2025.
Lucid Diagnostics recognized $1.5 million in EsoGuard revenue for the second quarter and processed 2,770 EsoGuard tests.
Veris Health is targeting an early 2027 FDA 510(k) submission for its implantable physiological monitor.
Sinda Ltd., a silver exploration company listed on the NYSE, reported a second-quarter 2026 net loss of $16.6 million, compared with $2.2 million in the same quarter of 2025. The company attributed the increase to planned spending on its Phase 1 surface drilling program and higher general and administrative costs tied to its IPO. The filing reports no revenue figures, and shareholders' main takeaway is that the company raised $331.3 million in total gross proceeds and reports a combined post-IPO liquidity position of $320.7 million.
Net loss of $16.6 million for the three months ended June 30, 2026, versus $2.2 million in Q2 2025
Total gross proceeds of $331.3 million from the IPO, the July 15, 2026 overallotment exercise, and the Fresnillo concurrent placement
Cash of approximately $204.3 million at June 30, 2026; combined post-IPO liquidity of $320.7 million
Phase 1 surface drilling completed 60,810 meters; the exploration decline received environmental authorization in March 2026 with construction targeted for 2H 2026
Upland Software reported second quarter 2026 revenue of $49.1 million, down 8% year over year, and a GAAP net loss of $35.3 million after a non-cash goodwill impairment. The company cut its full-year 2026 revenue and Adjusted EBITDA outlook relative to 2025, with both expected to decline at the midpoint, so shareholders face weaker reported results and a lower near-term earnings base.
Q2 2026 total revenue was $49.1 million, down from $53.4 million, mainly due to divestitures completed in 2025.
GAAP net loss was $35.3 million versus $13.0 million a year earlier, driven by a $35.2 million non-cash impairment of goodwill and other intangibles recorded in June 2026.
Full-year 2026 revenue guidance is $190.1 million to $196.1 million, an 11% decline at the midpoint; Adjusted EBITDA guidance is $49.8 million to $52.8 million, a 12% decline at the midpoint.
Adjusted EBITDA was $12.8 million in Q2 2026 versus $13.6 million a year earlier, and cash on hand was $31.0 million at June 30, 2026.
Greenland Technologies reported unaudited results for the quarter ended June 30, 2026, in a press release furnished as Exhibit 99.1. Second-quarter revenue rose 37.6% to $29.9 million, and the company returned to profit, with net income of $4.9 million compared with a net loss of $2.8 million a year earlier. Earnings per share were $0.13 versus a loss of $0.20, and the filing gives no guidance for future periods.
Q2 revenue $29.9 million, up 37.6% from $21.7 million; sales volume up 24.1% to 53,243 sets
Q2 gross margin 31.9%, up from 26.5%; income from operations $6.0 million versus a $2.3 million loss
Net income attributable to shareholders $3.5 million; basic and diluted EPS $0.13 versus a $0.20 loss
First-half revenue $55.4 million, up 27.7%; cash and equivalents $8.98 million at June 30, 2026
Presurance Holdings reported second-quarter 2026 net income of $2.5 million, up from $2.1 million a year earlier, while earnings per share fell to $0.68 from $1.17 as the weighted share count rose to 3,746,114 from 1,746,125. Gross written premiums fell 38.0% to $13.1 million, and management attributed the decline to underwriting discipline and the runoff of commercial lines.
Q2 2026 net income was $2.5 million ($0.68 per share) versus $2.1 million ($1.17 per share) in Q2 2025
Combined ratio improved to 69.5% from 121.1%; six-month combined ratio was 86.4% versus 131.2%
Gross written premiums fell 38.0% to $13.1 million; net earned premiums fell 28.8% to $6.8 million
Book value was $7.41 per share at June 30, 2026, compared with $16.15 a year earlier
Boost Run reported second-quarter 2026 results, its first as a public company after a May 8, 2026 business combination. Revenue for the quarter was $31.1 million, up from $8.4 million a year earlier, and total long-term contracted revenue stands at $1.9 billion. The filing does not disclose net income or earnings per share for the quarter.
Q2 2026 total revenue was $31.1 million, up 270% from $8.4 million in the prior-year period.
Total long-term contracted revenue stands at $1.9 billion, with over $1 billion in contracts signed during the quarter.
Unrestricted cash was $120.2 million at June 30, 2026, including $114.1 million in net proceeds from the business combination.
Targets include about $400 million in annualized recurring revenue at the end of fiscal 2026 and a net cash flow margin of 15% to 20% in forward periods.
Suncrete reported second-quarter 2026 revenue of $97.2 million, up 146% from $39.5 million a year earlier, driven by recent acquisitions. The net loss widened to $37.1 million from $325,000, mainly due to a $26.9 million non-cash charge tied to the business combination and $12.2 million in acquisition-related costs. The company kept its 2026 guidance, which calls for revenue of $420 million to $480 million and a net loss of $(31) million to $(7) million.
Revenue was $97.2 million versus $39.5 million a year earlier; total yards delivered rose 123%.
Net loss was $37.1 million versus $325,000, including a $26.9 million non-cash charge and $12.2 million in acquisition-related costs.
Adjusted EBITDA was $13.5 million versus $7.0 million; Supplemental Adjusted EBITDA was $14.6 million versus $7.7 million.
2026 guidance was maintained: revenue of $420 million to $480 million and Adjusted EBITDA of $68 million to $93 million.
Replimune reported a fiscal first-quarter 2027 net loss of $69.8 million, or $0.72 per share, down from $86.7 million, or $0.95 per share, a year earlier, as research and development and selling, general and administrative expenses both fell. The company also said the FDA granted accelerated approval for TUDRIQEV on August 6, 2026, and expects product in the market within 60 days, while cash declined to $195.3 million at June 30, 2026.
Net loss was $69.8 million ($0.72 per share) for the quarter ended June 30, 2026, versus $86.7 million ($0.95 per share) a year earlier.
R&D expenses were $49.3 million versus $57.8 million, and SG&A expenses were $19.0 million versus $32.6 million.
Cash, cash equivalents and short-term investments were $195.3 million at June 30, 2026, down from $268.9 million at March 31, 2026; the company cites $141.0 million in net proceeds from an August 2026 stock issuance.
The FDA granted accelerated approval for TUDRIQEV on August 6, 2026; Michelle DiNapoli was appointed Chief Commercial Officer, effective August 18, 2026.
Galectin Therapeutics reported its June 30, 2026 quarterly results, with a net loss applicable to common stockholders of $9.2 million, or $0.14 per share, up from $7.6 million, or $0.12 per share, a year earlier. The increase was mainly due to a $3.2 million charge for the change in fair value of derivative liabilities, and the company also reported that a $105.8 million debt conversion into common stock strengthened its balance sheet and that it reached FDA alignment on its planned Phase 3 trial.
Q2 2026 net loss applicable to common stockholders was $9.2 million, or $0.14 per share, versus $7.6 million, or $0.12 per share, in Q2 2025
Chairman Richard Uihlein's conversion of about $105.8 million in debt and accrued interest into 34,376,167 common shares took effect July 31, 2026
Cash and cash equivalents were $13.2 million at June 30, 2026, with $10 million remaining under the chairman's line of credit; the company expects cash to fund planned operations through June 2027
The company expects to submit the registrational Phase 3 protocol for belapectin in the third quarter of 2026
LanzaTech reported second-quarter 2026 net income of $184.3 million, compared with a net loss of $32.5 million a year earlier, mainly because of a $208.1 million non-cash unrealized gain on its SGLT investment. Revenue slipped to $9.0 million from $9.1 million, while operating expenses fell to $11.7 million from $35.1 million and Adjusted EBITDA loss narrowed to $7.6 million from $29.7 million. The company also reintroduced 2026 guidance, with full-year revenue of $50 million to $55 million and full-year Adjusted EBITDA of $(22) million to $(26) million.
Net income of $184.3 million versus a net loss of $32.5 million, driven by the $208.1 million non-cash gain on the SGLT investment
Revenue of $9.0 million, down from $9.1 million; operating expenses of $11.7 million, down from $35.1 million
Adjusted EBITDA loss of $7.6 million, compared with $29.7 million in the second quarter of 2025
Reintroduced guidance: third-quarter 2026 revenue of $8 million to $11 million; full-year 2026 revenue of $50 million to $55 million and Adjusted EBITDA of $(22) million to $(26) million
Digi Power X reported revenue of approximately $6.6 million and a net loss of approximately $14.4 million for the quarter ended June 30, 2026, including its first AI compute revenue of approximately $1.1 million. The company also set a 2027 target of $250 million to $300 million in annualized revenue run-rate by Q3 2027, which depends on customer contracts, deployments and financing. For shareholders, the quarter shows early AI revenue alongside a large loss, and the outlook remains conditional on execution and financing.
Q2 2026 revenue of approximately $6.6 million and net loss of approximately $14.4 million
Adjusted EBITDA of approximately $3.3 million, compared with approximately $0.1 million in the prior-year period
2027 outlook targets an annualized revenue run-rate of $250 million to $300 million by Q3 2027
Cash of $142.4 million as of June 30, 2026; Goldman Sachs engaged to help syndicate Alabama data center debt financing
Teamshares reported second-quarter 2026 revenue of $148.7 million, up 20% from a year earlier, and net income of $9.5 million compared with a $12.9 million loss in the same period of 2025. The company reaffirmed its 2026 guidance of $60 million in Pro Forma Adjusted EBITDA, which assumes it completes transactions that provide additional capital for acquisitions. The net income improvement was helped by a non-cash $24.9 million gain from changes in the fair value of earnout share and deferred founder share liabilities.
Q2 2026 revenue was $148.7 million, up $25.1 million (20%) year over year; diluted EPS was $0.16 versus a $(0.26) loss a year earlier.
Adjusted EBITDA was $9.6 million, up $6.0 million (166%); Pro Forma Adjusted EBITDA was $9.8 million.
Full-year 2026 Pro Forma Adjusted EBITDA guidance of $60 million was reaffirmed, contingent on securing additional acquisition financing.
Non-binding letters of intent cover 10 businesses with about $30 million in annual EBITDA; a non-binding term sheet for a senior secured warehouse facility was entered on August 4, 2026.
Tvardi Therapeutics reported a second-quarter 2026 net loss of $6.5 million, compared with net income of $4.2 million a year earlier, which included a $12.7 million non-cash gain. The company also reported topline healthy volunteer results for TTI-109, selected ulcerative colitis as its initial indication, and said its cash runway reaches the HCC readout in the third quarter of 2027, with additional funding needed to advance TTI-109 in UC.
Net loss of $6.5 million for the quarter ended June 30, 2026, versus net income of $4.2 million in the same period of 2025; basic and diluted loss per share was $(0.69).
Research and development expenses fell to $4.0 million from $5.8 million, and general and administrative expenses fell to $2.6 million from $3.1 million.
Cash, cash equivalents and short-term investments were $15.8 million at June 30, 2026, down from $30.8 million at December 31, 2025.
A KOL webinar on TTI-109 in UC is scheduled for August 19, 2026; the UC trial start is planned for 2027, subject to IND clearance and additional funding.
VirTra reported second-quarter 2026 results on August 13, 2026, with revenue down 17% year over year to $5.8 million and a net loss of $0.3 million, compared with net income of $0.2 million a year earlier. The company said several customers booked in late 2025 could not accept delivery in the first half of 2026, and it ended June with $24.9 million in total backlog.
Q2 2026 revenue was $5.8 million, down from $7.0 million; gross margin was 59%, versus 69% a year earlier.
Q2 net loss was $0.3 million, or $0.02 per diluted share, compared with net income of $0.2 million, or $0.02 per share, in Q2 2025.
Six-month revenue was $9.2 million, down 35% from $14.1 million, and the six-month net loss was $1.6 million, or $0.14 per diluted share.
Total backlog at June 30, 2026 was $24.9 million, including $13.2 million in capital, $3.8 million in service, and $7.9 million in STEP contracts.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.